Literature DB >> 1425066

Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment.

W P Hopman1, P A Van Liessum, G F Pieters, J B Jansen, C B Lamers, A G Smals, G Rosenbusch, P W Kloppenborg.   

Abstract

The increased risk of gallstone formation in acromegalics treated with the somatostatin analog octreotide has been related to an impaired gallbladder emptying. To determine the duration of these inhibitory effects, meal-stimulated gallbladder motility, plasma cholecystokinin (CCK), and pancreatic polypeptide (PP) were measured in five acromegalics treated for 6-32 months with 200-300 micrograms octreotide daily. Meal tests were performed 45 min, 8 hr and two weeks after the last 100-micrograms subcutaneous dose. Results were compared with those in normal subjects. Integrated postprandial gallbladder contraction (-125 +/- 194 cm3/120 min) and integrated PP secretion (-0.1 +/- 0.2 nmol/liter/120 min) were completely suppressed in the 45-min study, but significantly improved (P < 0.05) when measured 8 hr (1376 +/- 322 cm3/120 min and 3.0 +/- 1.0 nmol/liter/120 min) and two weeks (1437 +/- 263 cm3/120 min and 10.6 +/- 1.6 nmol/liter/120 min) after the last dose of octreotide. The integrated gallbladder contraction in acromegalics at 8 hr was comparable to that at two weeks and to that in normal subjects, but the integrated PP response at 8 hr was significantly smaller (P < 0.05 vs two weeks and vs normals). Integrated plasma CCK secretion at 45 min (0.13 +/- 0.06 nmol/liter/120 min) was not statistically significantly different from the response at 8 hr (0.15 +/- 0.02 nmol/liter/120 min) and from that in normal subjects, but it was significantly increased at two weeks after cessation of octreotide (P < 0.05 vs 45 min and 8 hr).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425066     DOI: 10.1007/bf01299859

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

Authors:  P Hildebrand; C Beglinger; K Gyr; J B Jansen; L C Rovati; M Zuercher; C B Lamers; I Setnikar; G A Stalder
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

2.  Ultrasonographic study of gallbladder motility during total parenteral nutrition.

Authors:  N Cano; F Cicero; F Ranieri; J Martin; J di Costanzo
Journal:  Gastroenterology       Date:  1986-08       Impact factor: 22.682

3.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

4.  A computerized method for rapid quantification of gallbladder volume from real-time sonograms.

Authors:  W P Hopman; W F Brouwer; G Rosenbusch; J B Jansen; C B Lamers
Journal:  Radiology       Date:  1985-01       Impact factor: 11.105

5.  Does total parenteral nutrition induce gallbladder sludge formation and lithiasis?

Authors:  B Messing; C Bories; F Kunstlinger; J J Bernier
Journal:  Gastroenterology       Date:  1983-05       Impact factor: 22.682

6.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Authors:  R A Liddle; I D Goldfine; M S Rosen; R A Taplitz; J A Williams
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

7.  The role of the gallbladder in the pathogenesis of cholesterol gallstones.

Authors:  W W LaMorte; D J Schoetz; D H Birkett; L F Williams
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

8.  Effect of graded physiologic doses of cholecystokinin on gallbladder contraction measured by ultrasonography. Determination of threshold, dose-response relationships and comparison with intraduodenal bilirubin output.

Authors:  W P Hopman; P J Kerstens; J B Jansen; G Rosenbusch; C B Lamers
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

9.  Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration.

Authors:  W Londong; M Angerer; K Kutz; R Landgraf; V Londong
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

10.  Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma.

Authors:  A Koelz; M Kraenzlin; K Gyr; V Meier; S R Bloom; P Heitz; H Stalder
Journal:  Gastroenterology       Date:  1987-02       Impact factor: 22.682

View more
  2 in total

1.  Increased gall bladder volume in primary sclerosing cholangitis.

Authors:  P C van de Meeberg; P Portincasa; F H Wolfhagen; K J van Erpecum; G P VanBerge-Henegouwen
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

2.  Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.

Authors:  S H Hussaini; S P Pereira; M J Veysey; C Kennedy; P Jenkins; G M Murphy; J A Wass; R H Dowling
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.